GlassScriptPhysician profile
Kimberly Hamilton
NPI 1114206174
$2,383.48
in general payments reported to CMS, 2019-2025
27 companies · $750 in 2025
The $750 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $437 · 2023: $304 · 2024: $295 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.43 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $187.98 | 2021-2023 | |
| Harmony Biosciences LLC | $178.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.17 | 2021-2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $112.41 | 2021-2025 | |
| Csl Behring | $101.60 | 2025 | Hizentra |
| Avadel Cns Pharmaceuticals, LLC | $92.39 | 2025 | Lumryz |
| Ucb, INC. | $81.60 | 2025 | Rystiggo |
| Pfizer INC. | $77.11 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $65.12 | 2022-2023 | Hetlioz |
| Biogen, INC. | $55.94 | 2025 | Leqembi |
| Argenx US, INC. | $55.79 | 2025 | Vyvgart |
| Janssen Biotech, INC. | $52.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $47.82 | 2021-2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $45.59 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.83 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $39.73 | 2025 | Inbrija, Xeomin |
| Boston Scientific Corporation | $32.38 | 2023-2024 | Bodyguardian |
| Glaxosmithkline, LLC. | $31.88 | 2022-2023 | Shingrix |
| Tg Therapeutics, INC. | $24.52 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.91 | 2025 | Ultomiris |
| Baxter Healthcare | $19.82 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $16.05 | 2025 | Atriclip Laa Exclusion System |
| Sanofi-Aventis U.S. LLC | $15.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.